English-language podcasts

Podcasts

Blood Podcast

An episode can be the start of a conversation. Explore recent releases, share your thoughts, and meet through a ThinkMatch Roundtable.

Ask friends about this

Episodes to discuss

Blood Podcast

Prospective Study for VTE and a Phase II Study on Sapablursen

15 min

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Sabine Eichinger of the Medical University of Vienna, and Dr. Jeanne Palmer of the Mayo Clinic on their latest articles published in Blood highlighting emerging research and treatment strategies in hematology. Dr. Eichinger discusses a prospective study examining the risk of recurrent venous thromboembolism (VTE) in patients with provoked thrombosis, revealing that recurrence rates were higher than previously estimated, particularly among patients with major transient risk factors. Her findings suggest that recurrence risk is not uniform and that anticoagulation duration should be individualized rather than based on a one-size-fits-all approach. Dr. Jeanne Palmer then reviews a Phase II clinical trial of sapablursin, a novel hepcidin mimetic for polycythemia vera, explaining how the agent regulates iron availability to reduce erythropoiesis, decrease phlebotomy requirements, and potentially improve patients' qualit

Discuss this episode

Blood Podcast

Prothrombotic FVIII Mutation and Prime Editing T-Cells for Drug Resistance

31 min

In this week's episode, Blood editor Dr. Natalie Rosen interviews Dr. Lindsey George, Director of Clinical In Vivo Gene Therapy and an attending physician in the Division of Hematology at Children's Hospital of Philadelphia, and also Dr. Miles Horton and Dr. Thomas Lew of the Royal Melbourne Hospital and Peter McCallum Cancer Center, and the Walter and Eliza Hall Institute of Medical Research on their latest articles published in Blood on the characterization of the prothrombotic mechanisms of recombinant FVIII Aurora and turning immunosuppressants into tools for bidirectional in vivo control. Dr. George discusses "Factor VIII Aurora: a naturally occurring gain-of-function FVIII variant with enhanced FIXa affinity (https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2026034515)" and Drs. Horton and Lew discuss "Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression (https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.20260

Discuss this episode